Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women’s health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
Metrics to compare | ROVI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipROVIPeersSector | |
---|---|---|---|---|
P/E Ratio | 27.6x | 17.9x | −0.6x | |
PEG Ratio | −1.48 | 0.07 | 0.00 | |
Price/Book | 8.6x | 2.0x | 2.6x | |
Price / LTM Sales | 5.3x | 2.1x | 3.2x | |
Upside (Analyst Target) | 22.3% | 21.8% | 48.6% | |
Fair Value Upside | Unlock | 24.5% | 7.0% | Unlock |